Clinical Takeaway
Clinical trials show that cannabis-based products, particularly those containing THC, provide modest but measurable reductions in chronic pain compared to placebo. The evidence is categorized by THC-to-CBD ratio, source, and delivery method, reflecting that product composition meaningfully influences outcomes. Patients and clinicians should understand that benefits exist but are moderate, and individual product characteristics matter when considering cannabis for chronic pain management.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review provides updated evidence on cannabinoid efficacy and safety for chronic pain management, addressing clinical uncertainty about whether THC-CBD formulations offer meaningful pain relief compared to placebo across diverse patient populations. By synthesizing data through July 2025 with rigorous dual review of bias and evidence strength, the findings can inform prescribing decisions and help clinicians evaluate cannabinoids as adjunctive or alternative therapies within their pain management algorithms. The categorization by THC-to-CBD ratio clarifies which cannabinoid formulations may have differential clinical utility, enabling more targeted therapeutic selection for specific chronic pain conditions.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
🔬 This updated systematic review on cannabinoids for chronic pain provides valuable context for clinical decision-making, though several important limitations warrant careful interpretation. The restriction to randomized placebo-controlled trials strengthens internal validity but may miss real-world effectiveness data from observational studies, and the categorization by THC-to-CBD ratios acknowledges that cannabinoid formulations vary substantially in their pharmacology and likely clinical effects. Notably, heterogeneity in pain conditions, patient populations, dosing regimens, and study quality typically constrains the ability to draw firm conclusions about specific clinical applications, and publication bias remains a concern given the evolving regulatory landscape around cannabis research. For practitioners, this review underscores that while some cannabinoid preparations show promise for select chronic pain syndromes, the evidence base remains incomplete and individualized assessment of risks versus benefits remains essential before recommending these products to patients, particularly regarding drug interactions, cognitive effects, and long-term safety data that often lag behind clinical use.